These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

542 related items for PubMed ID: 8652851

  • 1. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR, Majewski D.
    Blood; 1996 Jun 15; 87(12):5355-69. PubMed ID: 8652851
    [Abstract] [Full Text] [Related]

  • 2. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo.
    Johnson BD, Truitt RL.
    Transplantation; 1992 Jul 15; 54(1):104-12. PubMed ID: 1631918
    [Abstract] [Full Text] [Related]

  • 3. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
    Johnson BD, Truitt RL.
    Blood; 1995 Jun 01; 85(11):3302-12. PubMed ID: 7756664
    [Abstract] [Full Text] [Related]

  • 4. Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene.
    Drobyski WR, Morse HC, Burns WH, Casper JT, Sandford G.
    Blood; 2001 Apr 15; 97(8):2506-13. PubMed ID: 11290616
    [Abstract] [Full Text] [Related]

  • 5. Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin.
    Blazar BR, Carroll SF, Vallera DA.
    Blood; 1991 Dec 01; 78(11):3093-102. PubMed ID: 1954395
    [Abstract] [Full Text] [Related]

  • 6. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice.
    Drobyski WR, Majewski D.
    Blood; 1997 Feb 01; 89(3):1100-9. PubMed ID: 9028343
    [Abstract] [Full Text] [Related]

  • 7. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Feb 01; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 8. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr 01; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 9. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD, Becker EE, LaBelle JL, Truitt RL.
    J Immunol; 1999 Dec 15; 163(12):6479-87. PubMed ID: 10586039
    [Abstract] [Full Text] [Related]

  • 10. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts.
    Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Vallera DA.
    Blood; 1995 May 01; 85(9):2607-18. PubMed ID: 7537122
    [Abstract] [Full Text] [Related]

  • 11. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 01; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 12. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
    Truitt RL, Atasoylu AA.
    Blood; 1991 Jun 01; 77(11):2515-23. PubMed ID: 2039833
    [Abstract] [Full Text] [Related]

  • 13. Analysis of cytokine production and V beta T-cell receptor subsets in irradiated recipients receiving portal or peripheral venous reconstitution with allogeneic bone marrow cells, with or without additional anti-cytokine monoclonal antibodies.
    Gorczynski RM, Chen Z, Zeng H, Gorczynski L, Terzioglu E.
    Immunology; 1998 Feb 01; 93(2):221-9. PubMed ID: 9616372
    [Abstract] [Full Text] [Related]

  • 14. Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens.
    Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Barrett TA, Bluestone JA, Vallera DA.
    Blood; 1996 Jan 15; 87(2):827-37. PubMed ID: 8555509
    [Abstract] [Full Text] [Related]

  • 15. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR, Majewski D, Ozker K, Hanson G.
    J Immunol; 1998 Sep 01; 161(5):2610-9. PubMed ID: 9725263
    [Abstract] [Full Text] [Related]

  • 16. A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers.
    Koch U, Korngold R.
    Blood; 1997 Apr 15; 89(8):2880-90. PubMed ID: 9108408
    [Abstract] [Full Text] [Related]

  • 17. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.
    Vallera DA, Taylor PA, Panoskaltsis-Mortari A, Blazar BR.
    Blood; 1995 Dec 01; 86(11):4367-75. PubMed ID: 7492798
    [Abstract] [Full Text] [Related]

  • 18. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
    Maeda T, Eto M, Lin T, Nishimura Y, Kong YY, Nomoto K, Nomoto K.
    J Immunol; 1994 Nov 01; 153(9):4311-20. PubMed ID: 7930630
    [Abstract] [Full Text] [Related]

  • 19. Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens.
    Blazar BR, Taylor PA, Bluestone JA, Vallera DA.
    Blood; 1996 May 15; 87(10):4463-72. PubMed ID: 8639809
    [Abstract] [Full Text] [Related]

  • 20. Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299.
    Annat J, Churaqui E, Dutartre P, Bruley-Rosset M.
    Transplantation; 1996 Sep 27; 62(6):721-9. PubMed ID: 8824467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.